USFDA issues CRL for proposed biosimilar Insulin-R: Biocon
The US Food and Drug Administration (USFDA) issues a Complete Response Letter (CRL) to convey to a company that its initial review…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon
Biocon starts clinical study to evaluate efficacy of Itolizumab
This is a phase-II randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two-treatment period…
‘Science 2022 Top Employer List’ recognises two Indian pharma companies
Biocon and Dr Reddy's have been recognised by 'Science' magazine in the top 10 and top 20 employers list, respectively
Advancements in oral dosage forms
Dr Rakesh Bhasin, Vice President and Head – R&D (Formulations), started his presentation by introducing 3D printing to the…
Biocon Q4FY22 revenue at Rs 2,476 crores, up 21 per cent
FY22 revenue at Rs 8,397 crores, up 14 per cent; core EBITDA up 18 per cent at Rs 2,669 crores; PBT (before Exceptional Item) at…
Kiran Mazumdar-Shaw Elected as Fellow of Royal Society of Edinburgh
Shaw is among the 80 luminaries to be appointed to the RSE’s Fellowship this year
We will have to see the fine print if there is anything for pharma
Kiran Mazumdar Shaw, Chairperson, Biocon, and Biocon Biologics, shares her reaction to the union budget 2022 released today
Biocon ties up with Tabuk Pharmaceuticals to commercialise speciality medicines in Middle East
Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products of…
Biocon gets US FDA nod for generic product
The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant and is available…